2005; Hendrikx et al. 2013; Topletz et al. 2013; Xiang et al. 2017). CYP3A4 has been revealed to mediate numerous drug-drug interactions. For example, amlodipine and atorvastatin are two commonly used drugs in the clinical treatment of hypertension and dyslipidemia (Curran 2010). The co-administration of these two drugs induced adverse drug-drug interaction due to the inhibition of CYP3A4 by atorvastatin (Yang et al. 2020). Here, CYP3A4 is linked to metabolic syndrome.